[Joint use of thyroid and antithyroid preparations].
On the model of the mammary gland cancer, induced by a carcinogen in rats, it is shown that thyroxine (in a dose approximately equal to the physiological one, which per se would stimulate neoplasia or renders no effect) increases the antineoplastic action of the thyroid function inhibitors when administered simultaneously. Thus, they may be considered a positive compensation factor. Simultaneous application of the thyroid hormone with a hypolipidemic preparation--cetamiphene seems to be mostly advantageous.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D013956:Antithyroid Agents / Q000008:administration & dosage*; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control; D051381:Rats; D013974:Thyroxine / Q000008:administration & dosage*; D013997:Time Factors
D013956:Antithyroid Agents; D015127:9,10-Dimethyl-1,2-benzanthracene; D013974:Thyroxine
O sovmestnom primenenii tireoidnykh i antitireoidnykh preparatov.